Tuesday, November 24, 2015 7:30:31 AM
"BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Announced Today the Stock is Halted
Date : 11/24/2015 @ 7:05AM
Source : GlobeNewswire Inc.
Stock : Biomarin Pharmaceutical Inc. (MM) (BMRN)
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Announced Today the Stock is Halted
Today : Tuesday 24 November 2015
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that NASDAQ has halted trading of the company’s stock. The Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) of the U.S. Food and Drug Administration (FDA) is meeting today to review BioMarin’s New Drug Application (NDA) for Kyndrisa, an investigational antisense oligonucleotide drug candidate for the treatment of patients with Duchenne muscular dystrophy amenable to exon 51 skipping.
The PCNS advisory meeting is scheduled for November 24 at 8:00 a.m. to 5:30 p.m. EST. The briefing materials and webcast information can be found on the FDA website at: www.fda.gov/AdvisoryCommittees/Calendar/ucm467180.htm
The Prescription Drug User Fee Act (PDUFA) action date for completion of FDA review of the Kyndrisa NDA is December 27, 2015.
About Duchenne Muscular Dystrophy
Changes in the dystrophin gene (mutations) that lead to the near absence of dystrophin protein result in the most severe form of dystrophin deficient muscular dystrophy, Duchenne muscular dystrophy, also known as just Duchenne. Boys living with Duchenne experience progressive muscle weakness, causing serious medical complications including serious heart or respiratory-related complications, resulting in death in early adulthood.
Primarily affecting boys, Duchenne affects approximately 1 in every 3,500-5,000 male children, making it the most common fatal genetic disorder diagnosed in childhood. There is currently no FDA approved therapy designed specifically to treat Duchenne.
About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.BMRN.com.
Investors
Traci McCarty
BioMarin Pharmaceutical Inc.
(415) 455-7558
Media
Debra Charlesworth
BioMarin Pharmaceutical Inc.
(415) 455-7451"
"It is difficult to get a man to understand something, when his salary depends upon his not understanding it."
Upton Sinclair
"Nobody ever went broke underestimating the intelligence of the American public."
H. L. Mencken
Recent BMRN News
- BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society Meeting • PR Newswire (US) • 09/18/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/17/2024 09:54:07 PM
- BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance • PR Newswire (US) • 09/04/2024 05:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/04/2024 04:52:34 PM
- BioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time • PR Newswire (US) • 09/04/2024 11:30:00 AM
- BioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7:45 AM PT / 10:45 AM ET in New York, NY • PR Newswire (US) • 08/29/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2024 09:02:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/22/2024 09:00:30 PM
- BioMarin Announces New R&D and Business Development Leadership • PR Newswire (US) • 08/21/2024 12:30:00 PM
- BioMarin to Host 2024 Investor Day on September 4th in New York • PR Newswire (US) • 08/19/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/15/2024 07:57:07 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/13/2024 03:48:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/05/2024 08:35:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 08:05:28 PM
- BioMarin Announces 20% Y/Y Total Revenue Growth in the Second Quarter and Increase in Full-year 2024 Guidance • PR Newswire (US) • 08/05/2024 08:03:00 PM
- BioMarin Announces Updated Strategy for ROCTAVIAN® to Focus on U.S., Germany and Italy • PR Newswire (US) • 08/05/2024 08:01:00 PM
- U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease • PR Newswire (US) • 07/24/2024 08:05:00 PM
- BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET • PR Newswire (US) • 07/23/2024 12:00:00 PM
- BioMarin to Present Data Highlighting Significant Impact of VOXZOGO® (vosoritide) in Bone Health and Health-Related Quality of Life in Achondroplasia at 2024 International Conference on Children's Bone Health • PR Newswire (US) • 06/17/2024 12:30:00 PM
- KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 • PR Newswire (US) • 06/07/2024 10:09:00 PM
- BioMarin Presents New Phase 3, Four-Year Data Underscoring Long-Term Safety and Efficacy of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2024 Congress • PR Newswire (US) • 06/07/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 11:28:12 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/04/2024 02:18:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 10:28:05 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/31/2024 02:49:42 PM
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM